Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
05 2023
Historique:
received: 28 12 2022
revised: 28 02 2023
accepted: 18 04 2023
medline: 30 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Gynecologic carcinosarcomas (CS) are biphasic neoplasms composed of carcinomatous (C) and sarcomatous (S) malignant components. Because of their rarity and histologic complexity, genetic and functional studies on CS are scarce and the mechanisms of initiation and development remain largely unknown. Whole-genome analysis of the C and S components reveals shared genomic alterations, thus emphasizing the clonal evolution of CS. Reconstructions of the evolutionary history of each tumor further reveal that C and S samples are composed of both ancestral cell populations and component-specific subclones, supporting a common origin followed by distinct evolutionary trajectories. However, while we do not find any recurrent genomic features associated with phenotypic divergence, transcriptomic and methylome analyses identify a common mechanism across the cohort, the epithelial-to-mesenchymal transition (EMT), suggesting a role for nongenetic factors in inflicting changes to cellular fate. Altogether, these data accredit the hypothesis that CS tumors are driven by both clonal evolution and transcriptomic reprogramming, essential for susceptibility to transdifferentiation upon encountering environmental cues, thus linking CS heterogeneity to genetic, transcriptomic, and epigenetic influences. We have provided a detailed characterization of the genomic landscape of CS and identified EMT as a common mechanism associated with phenotypic divergence, linking CS heterogeneity to genetic, transcriptomic, and epigenetic influences.

Identifiants

pubmed: 37377900
doi: 10.1158/2767-9764.CRC-22-0520
pii: CRC-22-0520
pmc: PMC10171113
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

830-841

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Breast Cancer Res. 2010;12(2):R21
pubmed: 20346151
Cancer Cell. 2017 Mar 13;31(3):411-423
pubmed: 28292439
Genome Biol. 2015 Feb 13;16:35
pubmed: 25786235
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Methods. 2014 Nov;11(11):1138-1140
pubmed: 25262207
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
EMBO Mol Med. 2014 Sep 11;6(10):1279-93
pubmed: 25214461
Semin Cancer Biol. 2020 Apr;61:110-120
pubmed: 31622660
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Genome Biol. 2019 Oct 21;20(1):213
pubmed: 31639029
Neoplasia. 2017 Feb;19(2):100-111
pubmed: 28088687
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Commun. 2014 Sep 19;5:5006
pubmed: 25233892
Eur Urol. 2019 Jan;75(1):11-15
pubmed: 30245085
Mol Biol Cell. 2005 Mar;16(3):1131-41
pubmed: 15635089
Mod Pathol. 2011 Oct;24(10):1368-79
pubmed: 21572397
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2016 Jul 13;7:12222
pubmed: 27406316
Clin Chem. 2014 Sep;60(9):1192-9
pubmed: 24987110
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Science. 2017 Jul 21;357(6348):
pubmed: 28729483
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
Cancer Cell. 2018 Aug 13;34(2):197-210.e5
pubmed: 30017478
Nat Commun. 2019 Oct 31;10(1):4965
pubmed: 31672974
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083

Auteurs

Anne-Sophie Sertier (AS)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Anthony Ferrari (A)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Roxane M Pommier (RM)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.
Centre Léon Bérard, Lyon, France.

Isabelle Treilleux (I)

Department of Pathology, Centre Léon Bérard, Lyon, France.

Sandrine Boyault (S)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.
Centre Léon Bérard, Lyon, France.

Mojgan Devouassoux-Shisheboran (M)

Department of Pathology, Hospices Civils de Lyon, Lyon, France.
Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

Janice Kielbassa (J)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.
Centre Léon Bérard, Lyon, France.

Emilie Thomas (E)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Laurie Tonon (L)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Vincent Le Texier (V)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Amandine Charreton (A)

Centre Léon Bérard, Lyon, France.

Anne-Pierre Morel (AP)

Centre Léon Bérard, Lyon, France.

Anne Floquet (A)

Institut Bergonié Comprehensive Cancer Centre, Bordeaux, France.

Florence Joly (F)

Centre François Baclesse, Caen, France.

Dominique Berton-Rigaud (D)

Institut de Cancérologie de l'Ouest René-Gauducheau, Saint-Herblain, France.

Gwenaël Ferron (G)

Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.

Laurent Arnould (L)

Department of Pathology, Centre Georges François Leclerc, Comprehensive Cancer Centre, Dijon, France.

Sabrina Croce (S)

Department of Biopathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux, France.

Guillaume Bataillon (G)

Service de Pathologie, Institut Curie, Paris, France.

Pierre Saintigny (P)

Centre Léon Bérard, Lyon, France.
Department of Translational Medicine, Centre Léon Bérard, Lyon, France.
Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

Eliane Mery-Lamarche (E)

Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.

Christine Sagan (C)

Institut de Cancérologie de l'Ouest René-Gauducheau, Saint-Herblain, France.

Aruni P Senaratne (AP)

Institut Curie, PSL Research University, Paris, France.

Ivo G Gut (IG)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Carrer Baldiri i Reixac 4, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Fabien Calvo (F)

Centre de Recherche des Cordeliers, Université de Paris-Cité, Paris France.

Alain Viari (A)

Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France.

Maria Ouzounova (M)

Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

Isabelle Ray-Coquard (I)

Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

Alain Puisieux (A)

Centre Léon Bérard, Lyon, France.
Institut Curie, PSL Research University, Paris, France.
Chemical Biology of Cancer Laboratory, CNRS UMR 3666, INSERM U1143, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH